Paragraph 7
The manufacturer must make such adequate and suitable arrangements as are necessary for carrying out in accordance with the F1UK marketing authorisation any tests of the strength, quality or purity of the medicinal products to which the UK marketing authorisation relates.
Annotations
Textual amendments
- F1
Word in Sch. 9 inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 52(3); 2020 c. 1, Sch. 5 para. 1(1)
Notes on Schedule 9
Textual amendments
- F1
Words in Sch. 9 heading substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 52(2); 2020 c. 1, Sch. 5 para. 1(1)